EGFRviii Protein (AA 25-378) (FITC,His-Avi Tag)
-
- Target Alle EGFRviii (EGFRv3) Produkte
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 25-378
- Spezies
- Human
-
Quelle
- HEK-293 Cells
- Aufreinigungstag / Konjugat
- Dieses EGFRviii Protein ist gelabelt mit FITC,His-Avi Tag.
- Verwendungszweck
- FITC-Labeled Human EGFRVIII Protein
- Sequenz
- Leu25-Ser378
- Produktmerkmale
- Recombinant FITC-Labeled Human EGFRVIII Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Leu25-Ser378.
- Reinheit
- > 95 % as determined by Tris-Bis PAGE
- Sterilität
- 0.22 μm filtered
- Endotoxin-Niveau
- Less than 1EU per μg by the LAL method.
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Supplied as 0.22μm filtered solution in PBS ( pH 7.4).
- Lagerung
- -80 °C
- Informationen zur Lagerung
- Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Andere Bezeichnung
- EGFRVIII (EGFRv3 Produkte)
- Hintergrund
- The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
- Molekulargewicht
- 41.6 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.
- NCBI Accession
- NP_001333870
-